Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Child & Adolescent Psychiatry
Published in: European Child & Adolescent Psychiatry 7/2006

01-10-2006 | ORIGINAL CONTRIBUTION

Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment

Authors: Stefan Gebhardt, MD, Fabian Härtling, MD, Markus Hanke, Markus Mittendorf, Frank M. Theisen, MD, Karin Wolf-Ostermann, Phillip Grant, Matthias Martin, MD, Christian Fleischhaker, MD, Eberhard Schulz, MD, Helmut Remschmidt, MD, PhD

Published in: European Child & Adolescent Psychiatry | Issue 7/2006

Login to get access

Abstract

Objective

To examine prevalence of movement disorders (MDs) such as tardive dyskinesia (TD), parkinsonism or akathisia in an adolescent population with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.

Method

Ninety-three patients (aged 19.6±2.2 years) were ascertained in this cross-sectional/retrospective study. 76 patients (81.7%) received atypical, 10 (10.8%) typical antipsychotics and 7 (7.5%) combinations of atypical/typical antipsychotics. MD symptoms were assessed using Tardive Dyskinesia Rating Scale (TDRS), Abnormal Involuntary Movement Scale (AIMS), Extrapyramidal Symptom Scale (EPS), Barnes Akathisia Scale (BAS).

Results

Movement disorder symptoms were found in 37 patients (39.8%) fulfilling strict/subthreshold criteria for TD (5.4/11.8%), parkinsonism (2.2/25.8%) or akathisia (1.1/11.8%), respectively. Patients treated with typical antipsychotics displayed a significantly higher EPS-score (P=0.036) and a tendency towards a higher BAS-score (P=0.061) compared to patients with atypical antipsychotics. Treatment durations with typical/atypical antipsychotics showed trends towards advantages of atypical antipsychotics with regard to parkinsonism/akathisia symptoms (P=0.061; P=0.054), but not with regard to TD symptoms (P=0.003), possibly due to confounding effects.

Conclusion

Under treatment with atypical antipsychotics MD symptoms are less prevalent and less pronounced than under typical antipsychotics. We speculate that the finding of relatively high prevalence rates of subthreshold MD symptoms may be, at least partially, explained by previous or combined therapy with typical antipsychotics.
Literature
1.
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696PubMed
2.
3.
Barnes TRE, Halstead SM (1988) A scale for rating drug-induced akathisia. Schizophr Res 1:249
4.
Beasley CM, Dellva MA (1999) Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during longterm treatment with olanzapine or haloperidol. Br J Psychiatry 174:23–30PubMed
5.
Brüne M, Bräuning P, Höffler J, Börner I, Krüger S (1999) Prävalenz neuroleptikabedingter Bewegungsstörungen bei schizophrenen Psychosen. In: Bräuning P (ed) Motorische Störungen bei schizophrenen Psychosen. Schattauer, Stuttgart, New York, pp. 107–115
6.
Bruun RD (1988) Subtile and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. Am J Psychiatry 145:621–624PubMed
7.
Brunn RD, Budmann CL (1996) Risperidone as a treatment for Tourette’s syndrome. J Clin Psychiatry 57:29–31
8.
Campbell M, Adams P, Perry R, Spencer EK, Overall JE (1988) Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 24:251–255PubMed
9.
Campbell M, Anderson LT, Meier M (1979) A comparison of haloperidol, behavior therapy, and their interaction in autistic children [proceedings]. Psychopharmacol Bull 15:84–86PubMed
10.
Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, Sachar EJ (1978) A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640–655PubMedCrossRef
11.
Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE (1997) Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Psychiatry 36:835–843
12.
Campbell M, Grega DM, Green WH, Bennett WG (1983) Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol 6:207–222PubMed
13.
Campbell M, Palij M (1985) Measurement of side-effects including tardive dyskinesia. Psychopharmacol Bull 21:1063–1075PubMed
14.
Caroff SN, Mann SC, Campbell EC, Sullivan KA (2002) Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63(Suppl 4):12–19PubMed
15.
Casey DE (1998) Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 59(Suppl 3):31–37PubMed
16.
Casey DE (1995) Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 10(Suppl 3):105–114PubMed
17.
Casey DE (1991) Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4:109–120PubMed
18.
Casey DE (2004) Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65(Suppl 9):25–28PubMed
19.
Cawthrone P, James A, Dell J, Seagroatt V (1994) Adolescent onset psychosis. A clinical and outcome study. J Child Psychol Psychiatry 35:1321–1332
20.
Chengappa KN, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J (1994) The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 55:142–145PubMed
21.
Chouinard G (2004) New nomenclature for drug-induced movement disorders including tardive dyskinesia. J Clin Psychiatry 65(Suppl 9):9–15PubMed
22.
Connor DE, Fletcher KE, Wood JS (2001) Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 62:967–974PubMedCrossRef
23.
Dalack GW, Becks L, Meador-Woodruff JH (1998) Tardive dyskinesia, clozapine, and treatment response. Prog Neuropsychopharmacol Biol Psychiatry 22:567–573PubMed
24.
DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R (1997) Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatr Res 74:129–140
25.
Dittmann R (2004) Efficacy, subjective well-being and safety of olanzapine in adolescent patients with schizophrenia: findings from a prospective open-label multicenter study. In: Remschmidt H, Belfer M (eds) Proceedings of the 16th World Congress of IACAPAP, Berlin, 22–26 August 2004. Steinkopff, Darmstadt, p. 25
26.
Fenn DS, Moussaoui D, Hoffmann WF, Kadri N, Bentounssi B, Tilane A, Khomeis M, Casey DE (1996) Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacol Berl 123:206–210
27.
Fenton WS, Wyatt RJ, McGlashan TH (1994) Risk factors for spontaneous dyskinesia. Arch Gen Psychiatry 51:643–650PubMed
28.
Findling RL, McNamara NK (2004) Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 65(Suppl 6):30–44PubMed
29.
Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509–516PubMed
30.
Fisman S, Steele M (1996) Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 6:177–190PubMed
31.
Fleischhaker C, Schulz E, Tepper K, Martin M, Hennighausen K, Remschmidt H (2005) Long-term course of adolescent schizophrenia. Schizophr Bull 31: 1–12
32.
Frank S, Djavadi N (1980) Tardive dyskinesia and parkinsonian effects in adolescent psychiatric inpatients. Paper presented at the Annual Meeting of the American Academy of Child Psychiatry, Chiacago, IL, October 18
33.
Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM (2001) A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11:239–250PubMed
34.
Gerlach J, Casey DE (1988) Tardive dyskinesia. Acta Psychiatr Scand 77:369–378PubMed
35.
Gervin M, Brown S, Lane A, Clarka M (1998) Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry 155:1202–1206PubMed
36.
Glazer WM (2000) Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Psychiatry 61:16–21
37.
Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC (1996) Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 6:251–257PubMed
38.
Gualtieri CT, Breuning SE, Schroeder SR, Quade D (1982) Tardive dyskinesia in mentally retarded children, adolescents and young adults. North Carolina and Michigan studies. Psychopharmacol Bull 18:62–65PubMed
39.
Gualtieri CT, Schroeder SR, Hicks RE, Quade D (1986) Tardive dyskinesia in young mentally retarded individuals. Arch Gen Psychiatry 43:335–340PubMed
40.
Guy W (1976) ECDEU assessment manual for psychopharmacology, revised edn. US Department of Health, Education and Welfare, Washington, DC
41.
Häfner H, Riecher A, Maurer K, Meissner S, Schmidtke A, Fätkenheuer B (1990) Ein Instrument zur retrospektiven Einschätzung des Erkrankungsbeginns bei Schizophrenie. Entwicklung und erste Ergebnisse. Z Klin Psychol 19:230–255
42.
Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R (2002) Nithsdale schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 181:422–427PubMed
43.
Held T, Weber T, Krausz H, Ahle G, Hager B, Alfter D, Schulze T, Knapp M, Maier W, Rietschel M (2000) Klinische Charakteristika von Patienten mit tardiven Dyskinesien. Fortschr Neurol Psychiatr 68:321–331PubMed
44.
de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, Tollefson GD (2004) The prevalence of tardive dyskinesia after a nine-month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatr Clin Neurosc 254:356–361
45.
Kane JM (1995) Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom DE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp. 1485–1496
46.
Kane JM (2004) Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 65(Suppl 9):16–20PubMed
47.
Kane JM, Dauphinais D, Barnes TRE, Adler LA, Riflkin A (1993) Assessing negative symptoms and extrapyramidal symptoms in schizophrenia: workshop report. Psychopharmacol Bull 29:45–49PubMed
48.
Kane JM, Smith JM (1982) Tardive dyskinesia: rate and risk factors, 1959–1979. Arch Gen Psychiatry 39:473–481PubMed
49.
Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22: 254–258PubMed
50.
Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, Borenstein M (1984) Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 20:387–389PubMed
51.
Klingelhöfer J, Spranger M (1997) Klinikleitfaden Neurologie, Psychiatrie: Untersuchungen, Diagnostik, Therapie, Notfall. Gustav Fischer Verlag, Ulm, Stuttgart, Jena, Lübeck
52.
Kraepelin E (1919) Dementia praecox und paraphrenie. E. & S. Livingston, Edinburgh
53.
Krausz M, Müller-Thompsen T (1993) Schizophrenia with onset in adolescence: a 11-year follow-up. Schizophr Bull 19:831–841PubMed
54.
Kumra S, Jacobsen LK, Lenane M, Karp BI, Frazier JA, Smith AK, Bedwell J, Lee P, Malanga CJ, Hamburger S, Rapoport JL (1998) Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Child Adolesc Psychiatry 37:377–385
55.
Kumra S, Jacobsen LK, Lenane M, Smith A, Lee P, Malanga CJ, Karp BI, Hamburger S, Rapoport JL (1998) Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Child Adolesc Psychiatry 37:221–227
56.
Lambert M, Moritz S, Haasen C, Naber D (2000) Umstellung von typischen auf atypische Neuroleptika. Richtlinien zur ambulanten und stationären Behandlung. Nervenarzt 71:859–875PubMed
57.
Latimer PR (1995) Tardive dyskinesia: a review. Can J Psychiatry 40(Suppl 2):49–54
58.
Lewis R (1998) Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensivity to extrapyramidal symptoms. Can J Psychiatry 43:596–604PubMed
59.
Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J (1991) The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503–510PubMed
60.
Lieberman JA, Hsiao JK (2006) Interpreting the results of the CATIE study. Psychiatr Serv 57:139PubMed
61.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353:1209–1223PubMed
62.
Llorca PM, Chereau I, Bayle FJ, Lancon C (2002) Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 17:129–138PubMed
63.
Magulac M, Landsverk J, Golshan S, Jeste DV (1999) Abnormal involuntary movements in neuroleptic-naive children and adolescents. Can J Psychiatry 44:368–373PubMed
64.
Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA (2002) Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140–147PubMed
65.
Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835PubMed
66.
Marsálek M (2000) Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 33(Suppl 11):14–33PubMed
67.
McAndrew JB, Case Q, Treffert DA (1972) Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. J Autism Child Schizophr 2:75–91PubMed
68.
McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K (2003) Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 13:75–82PubMed
69.
McConville BJ, Sorter MT (2004) Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 65(Suppl 6):20–29PubMed
70.
McCreadie RG, Thara R, Kamath S, Padmavathy R, Latha S, Mathrubootham N, Menon MS (1996) Abnormal movements in never-medicated Indian patients with schizophrenia. Br J Psychiatry 168:221–226PubMed
71.
McCreadie RG, Thara R, Padmavati R, Srinivasan TN, Jaipurkar SD (2002) Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonance imaging study. Arch Gen Psychiatry 59:332–336PubMed
72.
McDermid SA, Hood J, Bockus S, D’Alessandro E (1998) Adolescents on neuroleptic medication: is this population at risk for tardive dyskinesia? Can J Psychiatry 43:629–631PubMed
73.
Meltzer HY, McGurk S (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233–255PubMed
74.
Miller CH, Fleischhacker WW (2000) Neurologische Neuroleptika-Nebenwirkungen. In: Förstl H (ed) Klinische Neuro-Psychiatrie. Neurologie psychischer Störungen und Psychiatrie neurologischer Erkrankungen. Thieme, Stuttgart, New York, pp. 449–478
75.
Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Liebermann JA (1998) The prevalence of acute extrapyramidal signs and symptoms in patients with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 59:69–75PubMed
76.
Modestin J, Stephan PL, Erni T, Umari T (2000) Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res 5:223–230
77.
Mozes T, Toren P, Chernauzan N, Mester R, Yoran-Hegesh R, Blumensohn R, Weizman A (1994) Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33:65–70PubMed
78.
Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37:372–376PubMed
79.
Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R (1997) Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 96:206–216PubMed
80.
Paulson GW, Rizvi CA, Crane GE (1975) Tardive Dyskinesia as a possible sequel of long-term therapy with phenothiazines. Clin Pediatry 14:953–955CrossRef
81.
Polizos P, Engelhardt DM (1980) Dyskinetic and neurolgical complications in children treated with psychotropic medication. In: Fann WE, Smith RC, Davis JM, Domino EF (eds) Tardive dyskinesia. Research and treatment. Spectrum Publications, Jamaica, New York, pp. 193–199
82.
Polizos P, Engelhardt DM (1978) Dyskinetic phenomena in children treated with psychotropic medications. Psychopharmacol Bull 14:65–68PubMed
83.
Polizos P, Engelhardt DM, Hoffman SP, Waizer J (1973) Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophr 3:247–253PubMed
84.
Potenza MN, Holmes JP, Kanes SJ, McDougle CJ (1999) Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37–44PubMed
85.
Reinbold H (1999) Biochemische Aspekte zur Entwicklung extrapyramidaler Störungen durch Antipsychotika. In: Bräuning P (ed) Motorische störungen bei schizophrenen psychosen. Schattauer, Stuttgart, New York, pp. 131–142
86.
Remschmidt H (2002) Early-onset schizophrenia as a progressive-deteriorating develomental disorder: evidence from child psychiatry. J Neural Transm 109:101–117PubMed
87.
Remschmidt H, Fleischhaker C, Henninghausen K, Schulz E (2000) Management of schizophrenia in children and adolescents. The role of clozapine. Paediatr drugs 2:253–262PubMed
88.
Remschmidt H, Henninghausen K, Clement HW, Heiser P, Schulz E (2000) Atypical neuroleptics in child- and adolescent psychiatry. Eur Child Adolesc Psychiatry 9(Suppl 1):9–19
89.
Remschmidt H, Schulz E, Martin M (1994) An open trial of clozapine in thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 4:31–41
90.
Richardson MA, Haugland G, Craig TJ (1991) Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factos in child and adolecent psychiatry patients. Am J Psychiatry 148:1322–1328PubMed
91.
Sachdev P (1995) Akathisia and restless legs. Cambridge University Press
92.
Sachdev P, Hume F, Toohey P, Doutney C (1996) Negative symptoms, cognitive dysfunction, tardive akathasia and tardive dyskinesia. Acta Psychiatr Scand 93:451–459PubMed
93.
Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB (2000) Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292–299PubMed
94.
Schmidt MH, Trott GE, Blanz B, Nissen G (1989) Clozapine medication in adolescents. In: Stefanis CN, Rabavilas AD, Soldatos CR (eds, 1990) Psychiatry: A World Perspective, Vol I. Proceedings of the VIII World Congress of Psychiatry, Athens, 12–19 October 1989. Excerpta Medica, Amsterdam, New York, Oxford, pp. 1100–1104
95.
Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486–487PubMed
96.
Schreier HA (1998) Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol 8:49–59PubMed
97.
Schulz E, Fleischhaker C, Remschmidt H (1999) Der Stellenwert typischer und atypischer Neuroleptika im Rahmen der Behandlung von schizophrenen Psychosen im Jugendalter. In: Fegert JM, Häßler F, Rothärmel S (eds) Atypische Neuroleptika in der Jugendpsychiatrie. Schattauer, Stuttgart, New York, pp. 141–167
98.
Schwartz TL, Saba M, Hardoby W, Virk S, Masand PS (2002) Use of atypical antipsychotics in a Veterans Affairs hospital. Prog Neuro-Psychopharmacol Biol Psychiatry 26:1207–1210
99.
Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M (2001) A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415–424PubMed
100.
Siefen G, Remschmidt H (1986) Behandlungsergebnisse mit Clozapin bei schizophrenen Jugendlichen. Z Kinder Jugendpsychiatr 14:245–257PubMed
101.
Simpson GM (2000) The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatr 61(Suppl 4):39–44
102.
Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 212:11–19
103.
Simpson GM, Lee JH, Zoubok B, Gardos G (1979) A rating scale for tardive dyskinesia. Psychopharmacology 64:171–179PubMed
104.
Sweet RA, DeSensi EG, Zubenko GS (1993) Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatr Clin Neurosc 5:56–60
105.
Tarsy D, Baldessarini RJ, Tarazi FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16:23–45PubMed
106.
Theisen FM, Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg J-C, Kühnau W, Schmidtke J, Remschmidt H, Hebebrand J (2005) Clozapine-induced weight gain: a study in monozygotic twins and same-sexed sib pairs. Psychiatr Genet 15:285–289PubMed
107.
Torrey EF (2002) Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr Res 58:101–115PubMed
108.
Turetz M, Mozes T, Toren P, Chernauzan N, Yoran-Hegesh R, Mester R, Wittenberg N, Tyano S, Weizman A (1997) An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry 170:507–510PubMed
109.
110.
Tuunainen A, Wahlbeck K, Gilbody S (2002) Newer atypical antipsychotic medication in comparison to clozapine: a systemic review of randomized trials. Schizophr Res 56:1–10PubMed
111.
Van Harten PN, Matroos GE, Hoek HW, Kahn RS (1996) The prevalence of tardive dystonia, tardive dyskinesia, parkinsonismus and akathisia. The Curacao Extrapryramidal Syndromes Study: I. Schizophr Res 19:195–203PubMed
112.
Vitello B, Jensen MD (1997) Medication development and testing in children and adolescents. Arch Gen Psychiatry 54:871–876
113.
Werry JS, McClellan JM, Chard L (1991) Childhood and adolescent schizophrenia, bipolar, and schizoaffektive disorder: A clinical and outcome study. J Am Acad Child Adolesc Psychiatry 30:457–465PubMedCrossRef
114.
Winsberg BG, Hurwic MJ, Sverd J, Klutch A (1978) Neurochemistry of withdrawal emergent symptoms in children. Psychopharmacology 56:157–161PubMed
115.
Wolf DV, Wagner KD (1993) Tardive dyskinesia, tardive dystonia, and tardive Tourette’s syndrome in children and adolescents. J Child Adolesc Psychopharmacol 3:175–198CrossRef
116.
Woods SW, Martin A, Spector SG, McGlashan TH (2002) Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 41:1439–1446PubMed
117.
Yassa R, Jeste DV (1997) Gender as a factor in the development of tardive dyskinesia. In: Yassa R, Nair V, Jeste DV (eds) Neuroleptic-induced movement disorders, 1st edn. Cambridge University Press, Cambridge, pp. 26–40
118.
Yassa R, Jeste DV (1992) Gender differences in tardive dyskinesia: a critical review of literature. Schizophr Bull 18:701–715PubMed
119.
Yuen O, Caligiuri MP, Williams R, Dickson RA (1996) Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. Br J Psychiatry 168: 702–708PubMedCrossRef
120.
Zhang ZJ, Zhang XB, Sha WW, Zhang XB, Reynolds GP (2002) Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7:670–671PubMed
Metadata
Title
Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment
Authors
Stefan Gebhardt, MD
Fabian Härtling, MD
Markus Hanke
Markus Mittendorf
Frank M. Theisen, MD
Karin Wolf-Ostermann
Phillip Grant
Matthias Martin, MD
Christian Fleischhaker, MD
Eberhard Schulz, MD
Helmut Remschmidt, MD, PhD
Publication date
01-10-2006
Publisher
Steinkopff-Verlag
Published in
European Child & Adolescent Psychiatry / Issue 7/2006
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-006-0544-5

Other articles of this Issue 7/2006

European Child & Adolescent Psychiatry 7/2006 Go to the issue

ORIGINAL CONTRIBUTION

Children aged 4–8 years treated with parent training and child therapy because of conduct problems: generalisation effects to day-care and school settings

ORIGINAL CONTRIBUTION

The effect of birth-weight with genetic susceptibility on depressive symptoms in childhood and adolescence

ORIGINAL CONTRIBUTION

Impaired working speed and executive functions as frontal lobe dysfunctions in young first-degree relatives of schizophrenic patients

ORIGINAL CONTRIBUTION

Suicide in Austrian children and young adolescents aged 14 and younger

ORIGINAL CONTRIBUTION

Ethnic differences in parental detection of externalizing disorders

ORIGINAL CONTRIBUTION

The continuity of psychopathology from early childhood to preadolescence